Effect of atazanavir versus other protease inhibitor-containing antiretroviral therapy on endothelial function in HIV-infected persons: Randomised controlled trial

Heart

Volumn 95, Issue 5, 2009, Pages 385-390

  Flammer, A J ^a   Vo, N T T ^a   Ledergerber, B ^a   Hermann, F ^a   Gamperli A ^a   Huttner, A ^a   Evison, J ^b   Baumgartner, I ^b   Cavassini, M ^c   Hayoz, D ^c   Quitzau, K ^a   Hersberger, M ^d   Sudano, I ^a   Ruschitzka, F ^a   Luscher T F ^a   Noll, G ^a   Weber, R ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; C REACTIVE PROTEIN; DIDANOSINE PLUS STAVUDINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDINAVIR PLUS RITONAVIR; LAMIVUDINE PLUS STAVUDINE; LAMIVUDINE PLUS TENOFOVIR; LAMIVUDINE PLUS ZIDOVUDINE; LIVER ENZYME; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NELFINAVIR; RITONAVIR; TENOFOVIR PLUS ZIDOVUDINE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ARTERY DILATATION; ARTICLE; BRACHIAL ARTERY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENDOTHELIAL DYSFUNCTION; ENZYME BLOOD LEVEL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; LIPID OXIDATION; MALE; MULTICENTER STUDY; OUTPATIENT CARE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; VASCULAR ENDOTHELIUM; VIRUS REPLICATION;

ADOLESCENT; ADULT; AGED; ENDOTHELIUM, VASCULAR; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LIPIDS; LIVER; MALE; MIDDLE AGED; OLIGOPEPTIDES; OXIDATIVE STRESS; PROSPECTIVE STUDIES; PYRIDINES; YOUNG ADULT;

EID: 61949412515     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2007.137646     Document Type: Article

References (25)

1. Periard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 1999;100:700-5.
2. Sudano I, Spieker LE, Noll G, et al. Cardiovascular disease in HIV infection. Am Heart J 2006;151:1147-55.
3. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003;349:1993-2003.
4. Henry K, Melroe H, Huebsch J, et al. Severe premature coronary artery disease with protease inhibitors. Lancet 1998;351:1328.
5. Holmberg SD, Moorman AC, Williamson JM, et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002;360:1747-8.
6. Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007;356:1723-35.
7. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-8.
8. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000;101:1899-906.
9. Solages A, Vita JA, Thornton DJ, et al. Endothelial function in HIV-infected persons. Clin Infect Dis 2006;42:1325-32.
10. Charakida M, Donald AE, Green H, et al. Early structural and functional changes of the vasculature in HIV-infected children: impact of disease and antiretroviral therapy. Circulation 2005;112:103-9.
11. Stein JH, Klein MA, Bellehumeur JL, et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001;104:257-62.
12. Hurlimann D, Chenevard R, Ruschitzka F, et al. Effects of statins on endothelial function and lipid profile in HIV infected persons receiving protease inhibitor-containing anti-retroviral combination therapy: a randomised double blind crossover trial. Heart 2006;92:110-12.
13. Cahn PE, Gatell JM, Squires K, et al. Atazanavir - a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized clinical trials. J Int Assoc Physicians AIDS Care (Chicago, Ill) 2004;3:92-8.
14. Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002;39:257-65.
15. Deanfield J, Donald A, Ferri C, et al. Endothelial function and dysfunction. Part I: Methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005;23:7-17.
16. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992;340:1111-15.
17. Sorensen KE, Celermajer DS, Georgakopoulos D, et al. Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein(a) level. J Clin Invest 1994;93:50-5.
18. Shankar SS, Dube MP, Gorski JC, et al. Indinavir impairs endothelial function in healthy HIV-negative men. Am Heart J 2005;150:933. e1-933. e7.
19. Wang X, Chai H, Yao Q, et al. Molecular mechanisms of HIV protease inhibitor-induced endothelial dysfunction. J Acquir Immune Defic Syndr 2007;44:493-9.
20. Zhong DS, Lu XH, Conklin BS, et al. HIV protease inhibitor ritonavir induces cytotoxicity of human endothelial cells. Arterioscler Thromb Vasc Biol 2002;22:1560-6.
21. Jiang B, Hebert VY, Zavecz JH, et al. Antiretrovirals induce direct endothelial dysfunction in vivo. J Acquir Immune Defic Syndr 2006;42:391-5.
22. Mondal D, Pradhan L, Ali M, et al. HAART drugs induce oxidative stress in human endothelial cells and increase endothelial recruitment of mononuclear cells: exacerbation by inflammatory cytokines and amelioration by antioxidants. Cardiovasc Toxicol 2004;4:287-302.
23. Sulkowski MS. Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors. Clin Infect Dis 2004;385:S90-7.
24. Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006;166:1632-41.
25. Schindhelm RK, Diamant M, Bakker SJ, et al. Liver alanine aminotransferase, insulin resistance and endothelial dysfunction in normotriglyceridaemic subjects with type 2 diabetes mellitus. Eur J Clin Invest 2005;35:369-74.